Published in Am Heart J on October 01, 2006
Bowditch Revisited: Defining the Optimum Heart Rate Range in Chronic Heart Failure | NCT02563873
Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2014) 2.21
Normal limits of gated blood pool SPECT count-based regional cardiac function parameters. Int J Cardiovasc Imaging (2008) 0.95
Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? Can J Cardiol (2008) 0.88
Prognostic significance of heart rate in hospitalized patients presenting with myocardial infarction. World J Cardiol (2012) 0.81
Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand? Cardiovasc Ther (2013) 0.77
Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker? J Geriatr Cardiol (2011) 0.77
Carvedilol in the treatment of elderly patients with chronic heart failure. Clin Interv Aging (2008) 0.77
Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena? Indian Pacing Electrophysiol J (2009) 0.75
Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev (2013) 0.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ (2007) 5.02
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J (2007) 2.59
Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J (2003) 2.37
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Intravascular and extravascular microvessel formation in chronic total occlusions a micro-CT imaging study. JACC Cardiovasc Imaging (2010) 2.17
A systematic review of telemonitoring for the management of heart failure. Eur J Heart Fail (2003) 2.17
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol (2012) 2.11
Flexible real-time magnetic resonance imaging framework. Conf Proc IEEE Eng Med Biol Soc (2004) 2.11
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail (2005) 2.06
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med (2006) 1.93
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail (2009) 1.88
The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J (2008) 1.85
Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail (2012) 1.82
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J (2011) 1.81
Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. Eur Heart J (2007) 1.81
Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J (2005) 1.81
Rapid multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart. Magn Reson Med (2010) 1.80
Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J (2007) 1.69
The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail (2005) 1.68
Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J (2007) 1.65
Hybrid intravascular ultrasound and optical coherence tomography catheter for imaging of coronary atherosclerosis. Catheter Cardiovasc Interv (2012) 1.64
Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging (2005) 1.63
IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging (2013) 1.59
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol (2007) 1.58
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail (2014) 1.58
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med (2005) 1.54
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail (2003) 1.54
Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2010) 1.51
Prognostic significance of different measures of the ventilation-carbon dioxide relation in patients with suspected heart failure. Eur J Heart Fail (2011) 1.48
Atherosclerotic renovascular disease in chronic heart failure: should we intervene? Eur Heart J (2005) 1.48
Is taking part in clinical trials good for your health? A cohort study. Eur J Heart Fail (2009) 1.46
The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail (2010) 1.43
Relationship between initial treatment strategy and quality of life in patients with coronary chronic total occlusions. EuroIntervention (2014) 1.41
Biomechanical efficiency is impaired in patients with chronic heart failure. Eur J Heart Fail (2007) 1.41
Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failure. Heart (2014) 1.41
Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail (2005) 1.40
A case of cough and breathlessness. Thorax (2012) 1.40
Calcium supplements in people with osteoporosis. BMJ (2010) 1.39
Is research declining amongst gastroenterology trainees in the United Kingdom? Clin Med (2013) 1.39
[Almanac 2011: heart failure. An editorial overview of selected research that has driven recent advances in clinical cardiology]. G Ital Cardiol (Rome) (2011) 1.39
Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. Eur J Heart Fail (2013) 1.39
Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail (2006) 1.38
Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail (2012) 1.36
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J (2006) 1.36
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J (2008) 1.33
Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail (2009) 1.32
Enlisting the help of the largest health care workforce--patients. JAMA (2010) 1.31
The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. Eur Heart J (2005) 1.30
Time-resolved MR angiography with limited projections. Magn Reson Med (2007) 1.28
The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J (2003) 1.28
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27
Exploring symptoms in chronic heart failure. Eur J Heart Fail (2005) 1.25
Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J (2005) 1.24
Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with quantitative two-dimensional color Doppler tissue imaging. J Am Soc Echocardiogr (2003) 1.24
Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail (2004) 1.24
Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study. Eur J Heart Fail (2009) 1.22
Electrostatic forward-viewing scanning probe for Doppler optical coherence tomography using a dissipative polymer catheter. Opt Lett (2008) 1.20
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J (2006) 1.20